Zai Lab announces NDA for sulbactam-durlobactam granted priority review by China’s NMPA

Zai Lab

30 January 2023 - Zai Lab today announced that the Center for Drug Evaluation of China’s National Medical Products Administration has granted priority review status to the new drug application for sulbactam with durlobactam for the treatment of infections caused by Acinetobacter baumannii, including multi-drug resistant and carbapenem-resistant strains.

Zai Lab has an exclusive license to develop and commercialise sulbactam with durlobactam in Greater China (mainland China, Hong Kong, Taiwan and Macau), Korea, Vietnam, Thailand, Cambodia, Laos, Malaysia, Indonesia, the Philippines, Singapore, Australia, New Zealand and Japan.

Read Zai Lab press release

Michael Wonder

Posted by:

Michael Wonder